Carcinoid Crisis: The Octreotide Shield

If you're like me, carcinoid tumors are a fascinating nightmare. The physiology is elegant — neuroendocrine cells secreting serotonin, histamine, and kinins — but the intraoperative crisis is anything but elegant. A carcinoid crisis presents with explosive flushing, bronchospasm, and hemodynamic collapse within seconds of tumor manipulation. On the anesthesiology oral boards, this scenario tests whether you know the one drug that works and the standard ACLS drug that can make everything worse.

Most carcinoid tumors originate in the GI tract. The key anesthetic implication: primary GI carcinoids are metabolized by the liver before reaching the systemic circulation — so they cause symptoms only when they metastasize to the liver (bypassing first-pass metabolism). When you're doing a hepatic resection on a patient with carcinoid liver mets, you are working directly in the storm.

The Core Logic

Carcinoid crisis is a massive, sudden release of vasoactive mediators — primarily serotonin and histamine. Serotonin causes vasoconstriction and bronchospasm; histamine causes vasodilation and bronchospasm. The net result is unpredictable and can swing either direction hemodynamically. Octreotide works by binding to somatostatin receptors on the tumor cells, directly suppressing mediator release. It is your antidote, your first-line treatment, and your prophylaxis — all in one.

The reason standard vasopressors are dangerous: catecholamines (epinephrine, dopamine) can directly stimulate carcinoid tumors to release more mediators. You treat the hemodynamic crisis and simultaneously make the underlying cause worse. Octreotide breaks the cycle without triggering more release.

How the Examiner Tests This

Classic scenario: patient with known carcinoid and hepatic mets is undergoing a hepatic resection. Mid-case, the blood pressure drops to 60/40, the face flushes, and bronchospasm develops. The examiner watches to see if you reach for epinephrine.

Common probes: "The BP is 55 systolic and the patient is in V-fib — would you use epinephrine?" This is the hardest version of the question. Yes, in a cardiac arrest, epinephrine is still appropriate — ACLS takes priority. The carcinoid nuance applies to hemodynamically unstable but not-yet-arrested patients, where alternatives like vasopressin or octreotide itself should be tried first. Know that distinction.

The Board Trap

The epinephrine trap. Carcinoid crisis with hypotension looks exactly like anaphylaxis — the automatic response is epinephrine. If you push epinephrine into a carcinoid patient who isn't in cardiac arrest, you're potentially triggering a second, larger wave of mediator release from the tumor. This can convert a manageable crisis into a fatal one.

The second trap: failing to pre-treat. A consultant who knows the patient has carcinoid doesn't wait for the crisis to give octreotide. You start an octreotide infusion before induction and have boluses prepared. Saying "I'll have octreotide ready" is good. Saying "I'll start a prophylactic infusion before skin incision" is a consultant answer.

Lead-In Phrases

• "For this patient with known carcinoid and hepatic metastases, I will start a prophylactic octreotide infusion at 50-100 mcg/hr before induction and have 500 mcg IV boluses immediately available at the field."
• "I will treat any hemodynamic instability as a presumptive carcinoid crisis — I'll push 100-500 mcg of octreotide immediately and repeat as needed."
• "I will avoid catecholamines as first-line vasopressors — epinephrine and dopamine can directly stimulate carcinoid tumor cells to release more mediators and worsen the crisis. I will prefer vasopressin for blood pressure support."
• "I will avoid histamine-releasing drugs — including morphine, atracurium, and succinylcholine — in any patient with known carcinoid."
• "I will discuss with the surgical team that tumor manipulation is the highest-risk moment — I want prior warning before they handle the liver directly."

FAQs

What is the dose of octreotide for an acute crisis?

For an acute carcinoid crisis, 100-500 mcg IV is the standard bolus, repeated every few minutes until the hemodynamics stabilize. In severe, refractory crisis, doses up to 1000 mcg have been described. The drug has a fast onset — you should see a response within 1-2 minutes. If there's no response after 1-2 doses, something else is contributing to the hemodynamic instability.

What if the patient was not known to have carcinoid preoperatively?

This does happen — an undiagnosed GI carcinoid with liver mets presents as sudden intraoperative hemodynamic collapse. Your differential includes anaphylaxis, MH, PE, and carcinoid crisis. The treatment approach converges: octreotide, avoid catecholamines, supportive care. If you're in doubt, give octreotide — it won't harm a non-carcinoid patient but will be lifesaving if it is carcinoid.

Is bronchospasm in carcinoid treated differently than standard bronchospasm?

Yes. Standard bronchospasm treatment includes epinephrine or albuterol — both catecholamines that can worsen carcinoid crisis. For carcinoid bronchospasm, octreotide is your primary bronchodilator. Inhaled ipratropium (anticholinergic) is an acceptable second line because it doesn't trigger mediator release.

Carcinoid crisis is one of those scenarios where knowing the one right drug — and the one dangerous drug — is the entire exam. Practice the "Hepatic Resection with Carcinoid Mets" scenario in Boards Bot until the word "epinephrine" triggers your octreotide reflex instead.